Therefore, this study aimed to classify ER+HER2- LABC patients with a high probability of providing an effective response to NAC using pretreatment MRI, which is a key modality for the non-invasive assessment of breast cancer [6,7,10]. This evidence concerns the gene ESR1 and breast carcinoma.